Supira Medical's FDA Approval Marks Key Advances in Cardiac Shock Treatment and Leadership Changes Supira Medical has received FDA approval for its SUPPORT II study, marking significant advancements in cardiac care and announces Keith Grossman to its board.

Supira Medical's FDA Approval Marks Key Advances in Cardiac Shock Treatment and Leadership Changes #USA #FDA_Approval #Los_Gatos #Supira_Medical #SUPPORT_II

Supira Medical Receives FDA Approval for SUPPORT II Study and Advances in Cardiogenic Shock Treatment Supira Medical announced the FDA's approval of its SUPPORT II study, marking a significant step in the treatment of cardiogenic shock and appointing D. Keith Grossman to its board.

Supira Medical Receives FDA Approval for SUPPORT II Study and Advances in Cardiogenic Shock Treatment #USA #Los_Gatos #Supira_Medical #SUPPORT_II #D._Keith_Grossman

Supira Medical Receives FDA Approval for SUPPORT II Study, Marks Breakthrough in Cardiogenic Shock Treatment Supira Medical has announced the FDA's approval for the SUPPORT II study, a major advancement in treating cardiogenic shock and the appointment of D. Keith Grossman to its board.

Supira Medical Receives FDA Approval for SUPPORT II Study, Marks Breakthrough in Cardiogenic Shock Treatment #USA #Los_Gatos #Supira_Medical #cardiogenic_shock #SUPPORT_II

Supira Medical Receives FDA Approval for SUPPORT II Trial and Strengthens Its Clinical Strategy Supira Medical has announced FDA approval for the SUPPORT II clinical trial, marking significant progress in treating cardiogenic shock and expanding treatment options.

Supira Medical Receives FDA Approval for SUPPORT II Trial and Strengthens Its Clinical Strategy #USA #Los_Gatos,_California #Supira_Medical #SUPPORT_II #kardiogenic_Schock

Supira Medical's FDA Trial Approval Marks a Crucial Step for Heart Care Innovations Supira Medical has received FDA approval for the SUPPORT II pivotal trial, enhancing treatment for cardiogenic shock and appointing new board member D. Keith Grossman.

Supira Medical's FDA Trial Approval Marks a Crucial Step for Heart Care Innovations #USA #FDA_Approval #Los_Gatos #Supira_Medical #pVAD

Supira Medical Achieves FDA Approval for Critical SUPPORT II Trial, Enhancing Treatment Options Supira Medical, Inc. announces FDA approval for its SUPPORT II trial, a vital step in enhancing cardiogenic shock treatment options and appoints D. Keith Grossman to its board.

Supira Medical Achieves FDA Approval for Critical SUPPORT II Trial, Enhancing Treatment Options #USA #Los_Gatos #Supira_Medical #pVAD #cardiogenic_shock

Supira Medical's FDA Approval for Pivotal SUPPORT II Trial Marks a Significant Step in Ventricular Device Advancement Supira Medical, Inc. has received FDA approval for its pivotal SUPPORT II trial, promising advancements in treating cardiogenic shock and enhancing patient mobility.

Supira Medical's FDA Approval for Pivotal SUPPORT II Trial Marks a Significant Step in Ventricular Device Advancement #USA #FDA_Approval #Los_Gatos #Supira_Medical #pVAD

Supira Medical Receives FDA Approval for Pivotal SUPPORT II Study Focusing on Cardiogenic Shock Supira Medical's recent FDA approval for the SUPPORT II clinical trial marks a significant step forward in treating patients with cardiogenic shock and highlights their leadership in medical innovation.

Supira Medical Receives FDA Approval for Pivotal SUPPORT II Study Focusing on Cardiogenic Shock #USA #Los_Gatos #Supira_Medical #SUPPORT_II #D._Keith_Grossman

Supira Medical Receives FDA Approval for Groundbreaking SUPPORT II Clinical Trial in Cardiogenic Shock Treatments Supira Medical has announced FDA approval for its SUPPORT II trial, marking a significant step in cardiogenic shock treatment advancements and leadership additions.

Supira Medical Receives FDA Approval for Groundbreaking SUPPORT II Clinical Trial in Cardiogenic Shock Treatments #USA #Los_Gatos #Supira_Medical #SUPPORT_II #D._Keith_Grossman

Supira Medical Raises $120M to Propel Innovative Heart Device Market Expansion Supira Medical successfully completed a $120M oversubscribed Series E financing to advance its cardiac support device technologies and clinical programs.

Supira Medical Raises $120M to Propel Innovative Heart Device Market Expansion #United_States #investors #Los_Gatos #Supira_Medical #pVAD